Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives $5.80 Average PT from Brokerages

Plus Therapeutics, Inc. (NASDAQ:PSTV) has received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $5.80.

PSTV has been the topic of a number of recent research reports. Lake Street Capital initiated coverage on Plus Therapeutics in a research report on Tuesday, February 3rd. They set a “buy” rating and a $2.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $1.00 price target (down from $2.00) on shares of Plus Therapeutics in a report on Friday, January 23rd. D. Boral Capital cut their price target on Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, January 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. Finally, Ascendiant Capital Markets decreased their price objective on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, November 21st.

Institutional Investors Weigh In On Plus Therapeutics

Institutional investors have recently bought and sold shares of the business. L1 Global Manager Pty Ltd bought a new stake in Plus Therapeutics in the 4th quarter valued at $1,167,000. Geode Capital Management LLC lifted its holdings in shares of Plus Therapeutics by 72.5% during the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after acquiring an additional 589,544 shares during the period. Jane Street Group LLC bought a new position in shares of Plus Therapeutics during the 4th quarter worth about $525,000. Altium Capital Management LLC acquired a new stake in shares of Plus Therapeutics during the 3rd quarter valued at about $628,000. Finally, Virtu Financial LLC acquired a new stake in shares of Plus Therapeutics during the 4th quarter valued at about $254,000. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Price Performance

Shares of Plus Therapeutics stock opened at $0.29 on Friday. The company has a market cap of $40.93 million, a PE ratio of -0.15 and a beta of 0.79. The firm has a fifty day moving average price of $0.32 and a two-hundred day moving average price of $0.48. Plus Therapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $2.08.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.25 earnings per share (EPS) for the quarter. The company had revenue of $1.37 million for the quarter. Analysts expect that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.